Évaluation de l’expression de PD-L1 en immunohistochimie : un biomarqueur émergent dans les carcinomes pulmonaires non à petites cellules
Author:
Publisher
Elsevier BV
Subject
Pathology and Forensic Medicine
Reference51 articles.
1. The future of immune checkpoint therapy;Sharma;Science,2015
2. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015
3. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015
4. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors;Eggermont;Oncoimmunology,2014
5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential;Sharma;Cell,2015
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Programmed death ligand-1 testing in adenocarcinoma lung: A comparative study of cell block versus biopsy;Journal of Cytology;2023
2. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden;Pathology - Research and Practice;2020-08
3. IHC, FISH, CISH, NGS dans les cancers bronchiques non à petites cellules : quelles évolutions dans l’ère des biomarqueurs ?;Revue de Pneumologie Clinique;2018-10
4. RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue;Radiation Oncology;2018-07-17
5. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?;Critical Reviews in Oncology/Hematology;2017-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3